Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Thursday

Black Diamond Therapeutics (NASDAQ:BDTX) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Black Diamond Therapeutics to post earnings of ($0.18) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its earnings results on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. On average, analysts expect Black Diamond Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Black Diamond Therapeutics Stock Performance

BDTX stock opened at $1.78 on Wednesday. The company has a fifty day moving average price of $1.86 and a 200-day moving average price of $2.28. The company has a market capitalization of $101.99 million, a P/E ratio of -2.31 and a beta of 3.28. Black Diamond Therapeutics has a 52-week low of $1.60 and a 52-week high of $4.94.

Institutional Investors Weigh In On Black Diamond Therapeutics

Several large investors have recently made changes to their positions in BDTX. nVerses Capital LLC bought a new stake in shares of Black Diamond Therapeutics during the 4th quarter worth $26,000. Hudson Bay Capital Management LP purchased a new stake in Black Diamond Therapeutics during the second quarter worth about $26,000. Cerity Partners LLC purchased a new stake in Black Diamond Therapeutics during the second quarter worth about $26,000. Stokes Family Office LLC bought a new stake in Black Diamond Therapeutics in the fourth quarter worth about $27,000. Finally, American Century Companies Inc. bought a new stake in Black Diamond Therapeutics in the second quarter worth about $30,000. 95.47% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on BDTX. BTIG Research lifted their price objective on Black Diamond Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Jefferies Financial Group raised Black Diamond Therapeutics to a “strong-buy” rating in a research report on Thursday, April 23rd. Wall Street Zen cut Black Diamond Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating on shares of Black Diamond Therapeutics in a report on Friday, May 22nd. Finally, Raymond James Financial reiterated an “outperform” rating on shares of Black Diamond Therapeutics in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.83.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.